"For the protection of the environment and ecology, we will go out of the way," Justice Gavai said. While posting the matter for the next hearing on May 15, the bench orally said, "In the meantime ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $502.55, marking a +0.45% move from the previous day. The stock's change was more than the S&P 500's daily loss of 0.33%.

Zimislecel (VX-880) pivotal trial on track to complete enrollment and dosing in H1 2025; Vertex expects to submit marketing applications to global regulators in 2026 - Vertex has completed ...

Vertex Solutions, a small business known for the manufacturing of systems integration and advanced training technologies, has been awarded a contract to deliver 25 additional T-38 Gen 2 enhanced ...

The hearing protection mode could be useful in environments like concerts, to help lower the loud volume and allow you to enjoy yourself without damaging your ears. The next time you connect your ...

Over the past 15 years, Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products. CRISPR Therapeutics won its first regulatory ...

Google Cloud’s latest enhancements to Vertex AI and the Gemini model family ... service controls providing multi-layered protection. Equally valuable is the platform's ability to connect agents ...

Ratings for Vertex VERX were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table below ...

AirPods Pro 2 users in Australia, Brazil, Saudi Arabia, Colombia, and Malaysia will soon have access to the hearing health feature set that Apple has been rolling out for the last several months.

After another solid year that included 12% growth in the top line, Vertex has bumped up its compensation for CEO Reshma Kewalramani, M.D., to $21.5 million, according to the company’s proxy filing.

Shares of Vertex have rallied, even amid the broader stock market sell-off. The company is diversifying beyond its dominance in cystic fibrosis treatments. Several catalysts in 2025 support a ...